BofA raised the firm’s price target on KalVista (KALV) to $37 from $22 and keeps a Buy rating on the shares after the company announced the approval of Ekterly for on-demand treatment of hereditary ...

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

Detailed price information for Kalvista Pharmaceuticals Inc (KALV-Q) from The Globe and Mail including charting and trades.

Health groups led by the American Academy of Pediatrics filed a lawsuit against HHS Secretary Robert F. Kennedy Jr. on Monday ...

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health ...

The domestic equity benchmarks ended with modest gains today, buoyed by positive sentiment after U.S. President Donald Trump postponed the implementation of new tariffs to August 1. The Nifty settled ...

Equity benchmarks closed higher today, buoyed by a late rally in banking and financial services stocks, with the Nifty ending above the 25,500 level. However, gains were capped by weakness in consumer ...

UnitedHealth Group Incorporated (NYSE:UNH) is one of the best high growth stocks. On June 25, UBS reiterated a Buy rating on ...

The FDA has approved garadacimab-gxii for prophylactic use in patients aged 12 years and older with hereditary angioedema, ...

A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) and diabetes therapy, rilparencel. There were statistically significant ...